Relationship between Microbial Translocation and Endothelial Function in HIV Infected Patients

Emily Blodget1,2, Changyu Shen3,5, Grace Aldrovandi2,6, Adrienne Rolli2,6, Samir K. Gupta4,5, James H. Stein7, Michael P. Dubé1,2

1 Department of Medicine, Division of Infectious Diseases, University of Southern California Keck School of Medicine, Los Angeles, California, United States of America, 2 University of Southern California Keck School of Medicine, Los Angeles, California, United States of America, 3 Department of Biostatistics, Indiana University School of Medicine, Indianapolis, Indiana, United States of America, 4 Department of Infectious Diseases, Indiana University School of Medicine, Indianapolis, Indiana, United States of America, 5 Indiana University School of Medicine, Indianapolis, Indiana, United States of America, 6 Department of Pediatrics, Children's Hospital of Los Angeles, Los Angeles, California, United States of America, 7 Division of Cardiovascular Medicine, University of Wisconsin School of Medicine and Public Health, Madison Wisconsin, United States of America

Abstract

**Background:** Circulating levels of microbial products are increased in HIV infection, and provoke endothelial dysfunction in other disease settings.

**Methodology/Principal Findings:** We examined data from a cross-sectional single site study at Indiana University (Indiana, N = 85) and a 24-week multicenter prospective study of antiretroviral therapy (ART) initiation (ACTG 5152s, N = 75). Brachial artery flow-mediated dilation (FMD) was measured by ultrasound. Plasma lipopolysaccharide (LPS) and soluble CD14 (sCD14) levels were measured from stored specimens and correlated with FMD values using Pearson correlations. The Indiana subjects were 63% male with a mean age of 39 years and a median CD4 count of 406 cells/mm³ (388 not on ART, 464 on ART). The 5152s subjects were 92% male with a mean age of 35 years and a median CD4 count of 251 cells/mm³ at entry which increased to 396 cells/mm³ on ART. When analyzing the two cohorts individually or in combination neither sCD14 nor LPS correlated significantly with FMD. In a pre-specified subgroup analysis of the Indiana subjects receiving ART (N = 46, mean ART duration 40 months) LPS was inversely correlated with FMD (r = -0.33, p = 0.02), but not sCD14 (r = -0.01, p = 0.9). Multivariate analysis confirmed LPS as an independent predictor of FMD in this subgroup (p = 0.02).

**Conclusions/Significance:** In HIV-infected individuals on prolonged ART, higher LPS levels are associated with worse endothelial function but not in untreated subjects or at 24 weeks after ART initiation. Persistent microbial translocation may contribute to arterial dysfunction and the increased cardiovascular disease risk observed in individuals on long-term ART.

Introduction

HIV infection has been associated with increased cardiovascular disease risk [1] but the mediators of the increased risk have not been specifically identified. Endothelial dysfunction is a critical initial step of atherogenesis which subsequently contributes to the progression and clinical manifestations of atherosclerosis [2,3]. Long-term use of protease inhibitors (PIs) has been associated with endothelial dysfunction [4]. Factors other than PI use that may contribute to endothelial dysfunction in HIV-infected patients include untreated HIV infection itself [5] treatment-associated lipid changes [4,6] and the lipodystrophy syndrome [7]. Mediators and markers of endothelial dysfunction have been sought, such as lipids and lipoproteins and circulating markers of inflammation and vascular activation, but the majority of these factors have not been significantly associated with endothelial function as measured by brachial flow-mediated dilation (FMD) [5,8]. Lack of a consistent association between FMD and CD4 cell count suggests that immune status is not directly related to endothelial dysfunction [5,8,9,10,11]. In a large cohort study, there was also no association between CD4 cell count and risk of myocardial infarction [12]. Despite careful study, the specific mediators of HIV-associated endothelial dysfunction have not been identified.

CD4+ T cell depletion in gut-associated lymphoid tissue (GALT) occurs within 4–6 weeks of primary HIV infection [13]. Simian immunodeficiency virus-infected macaque models have demonstrated that gut bacteria are a source of circulating bacterial lipopolysaccharide (LPS) [14]. CD4+ T-cell depletion in GALT coincides with increased expression of genes associated with inflammation and decreased expression of genes regulating epithelial barrier and digestive functions, mucosal repair and regeneration which suggests disruption of the gut microenvironment [13]. Increased levels of LPS that occur in patients with
chronic progressive HIV infection decreased after 48 weeks of effective anti-retroviral therapy (ART) but did not normalize [15]. These increased levels of LPS are associated with persistent immune activation [15], so by extension persistent immune activation itself is another potential mechanism of HIV-associated endothelial dysfunction.

Gut microbial translocation leads to increased circulating levels of LPS and other microbial products. LPS activates endothelial cells via a distinct signaling pathway and this may directly influence cardiovascular disease pathogenesis [16,17]. Soluble CD14 (sCD14) is a circulating glycoprotein that binds LPS, subsequently allowing the interaction of LPS with another signaling receptor. Cell associated CD14 is a multifunctional receptor, a glycoprotein expressed on the surface of monocytes, macrophages and neutrophils with a specificity for LPS and other bacterial wall derived components [16]. The presence of sCD14 is required for LPS-induced injury and activation of endothelial cells.

Our aim was to establish a relationship between microbial translocation measures and endothelial dysfunction in HIV-infected subjects in two well-characterized study populations [5,8] which used FMD as a marker of endothelial function. As has been shown in recent studies, impaired FMD has been associated with worse long-term cardiovascular disease prognosis [2,18]. A wide variety of inflammatory and vascular biomarkers were previously performed in both parent studies including high sensitivity C-reactive protein (hsCRP), lipids, lipoproteins, interleukin-6, adiponectin and vascular cell adhesion molecule-1 (VCAM-1) but none correlated with FMD.

Methods

Study subjects

Two distinct cohorts were examined. ACTG 5152s [5] was a substudy of ACTG 5142 [19] a prospective, multicenter, randomized clinical trial of ART initiation that examined endothelial function in HIV-infected, treatment-naïve subjects randomly assigned to 1 of 3 ART regimens and followed over 24 weeks. Exclusion criteria for A5152s included prior use of ART, known cardiovascular disease, diabetes mellitus or use of lipid-lowering medications [5]. The study was approved by the institutional review board at participating AIDS Clinical Trials Group sites.

The second study [8] was a single site study performed at Indiana University which enrolled unselected subjects from local primary HIV care clinics. Exclusion criteria, similar to 5152s included known cardiovascular disease, diabetes mellitus, active opportunistic infections, uncontrolled hypertension or renal insufficiency. This study was approved by the Indiana University institutional review board. In both studies, subjects consented to having blood specimens saved for possible future analyses.

The primary outcome measure was endothelial function, assessed by ultrasonic measurement of brachial artery FMD 60 seconds after lower forearm cuff release expressed as a percentage change, as previously described [5,8]. FMD exams from both studies were performed by technicians trained in the same laboratory using the same techniques and reading software.

Assays

Plasma samples preserved with EDTA were stored at −70°C until the time of assay. LPS was quantified using the Endotoxic LAL assay (Lonza, Basel, Switzerland) and sCD14 measurements were performed with the Quantikine ELISA from R&D systems (Minneapolis, MN) according to the manufacturer instructions. For both assays all samples were analyzed in triplicate.

Analyses

Subjects who had FMD, LPS and sCD14 measurements available were included for analysis. Whole group and pre-specified sub-group analyses included 5152s subjects at baseline and week 24 as well as the Indiana subjects as a whole, in addition to analysis of subgroups on ART and not on ART. Other subgroups considered were the combination of Indiana subjects on ART plus the 5152s subjects at week 24 (all ART-treated subjects), Indiana subjects not on ART plus the ART naïve baseline 5152s subjects (all subjects not on ART), Indiana ART-treated subjects with undetectable viral load (defined as ≤400 copies/mL) were analyzed alone as well as combined with those 5152s patients with undetectable viral load at week 24 (all subjects with undetectable viral load).

Pearson correlation coefficients were used to characterize the correlation between brachial FMD and LPS and sCD14. Paired T test was used to compare baseline and 24-week measures for the A5152s subjects. Linear regression was used to identify the independent contribution of LPS to the variation in brachial FMD controlling for gender, baseline brachial artery diameter, heart rate, systolic blood pressure and ART use. Because other inflammatory, lipid and HIV disease variables did not influence FMD in the parent studies [5,8] these were not considered in these analyses. Two-sided p-value of <0.05 was considered statistically significant. Analyses were not corrected for multiple comparisons in this exploratory study. All analyses were performed using SAS 9.2 (SAS Inc., Cary, NC).

Results

Subject Characteristics

There were 75 subjects from ACTG 5152s and 85 subjects from the Indiana University study that were included for a total of 160 patients in the primary analysis. The mean age of the A5152s subjects was 35 years with 92% male (Table 1). The median CD4 count was 251 cells/mm^3 at baseline; it increased to 391 cells/mm^3 at week 24. After 24 weeks, 92% had undetectable HIV RNA. There was a significant increase in LPS levels at 24 weeks compared to baseline (32 pg/mL vs. 40 pg/mL, p = 0.02) but no change in sCD14. As previously reported baseline brachial artery diameter in the A5152s groups was 0.44 cm.

The Indiana study was a cross-sectional study that included subjects on ART (n = 46) as well as those not on ART (n = 39) with the latter including both ART naïve and previously experienced subjects. The mean age was 40 years for those on ART and 38 years for those not on ART. For those on ART, the median CD4 count was 464 cells/mm^3; 322 cells/mm^3 for those not on ART. For individuals on ART, the proportion with undetectable HIV RNA was 84%; it was 11% for those not on ART. The median duration of ART in the treated group was 40 months. sCD14 levels were similar between groups. The mean LPS levels for those on ART was 33 pg/mL versus 26 pg/mL for those not on ART (p = 0.09). As previously reported [8] the Indiana cohort had a baseline brachial artery diameter of 0.40 cm which was similar in all groups.

Correlations with markers of microbial translocation

There was no significant correlation between brachial FMD and either sCD14 or LPS in the group as a whole. There also was no correlation between FMD and markers of translocation in the ACTG group either at baseline or at week 24, nor in the subjects.
not on ART in the Indiana cohort (Table 2). Combining all of the untreated subjects (Indiana cohort not on ART plus the ACTG group at baseline) there also was no significant correlation of FMD with either LPS or sCD14 (data not shown). Among the Indiana cohort on ART there was a negative correlation between LPS and brachial FMD ($r = -0.33$, $p = 0.02$) but no correlation with sCD14 (Table 2). After limiting the analysis to only those Indiana subjects with undetectable viral load ($N = 38$) a similar, significant inverse correlation between LPS and endothelial function was observed ($r = -0.36$, $p = 0.03$), but there was no significant relationship between FMD and sCD14.

When controlling for gender, baseline brachial artery diameter, heart rate, systolic blood pressure and ART use, LPS remained an independent predictor of FMD in those Indiana subjects on ART ($p = 0.02$). There was a progressive step-wise decrease in median % FMD across increasing tertiles of LPS levels (Figure 1) which was statistically significant ($p = 0.037$ by ANOVA). In the highest tertile of LPS levels (median 44.6 pg/ml [IQR 38.4, 62.8]), FMD was markedly impaired (median 2.76%).

**Discussion**

In subjects on prolonged ART (mean of 40 months) we observed a statistically significant negative correlation between LPS levels and FMD, suggesting that increased microbial translocation is associated with endothelial dysfunction in chronically ART-treated subjects. A significant relationship between LPS levels and FMD, suggesting that increased microbial translocation is associated with endothelial dysfunction in chronically ART-treated subjects. A significant relationship between

| Table 1. Subject Characteristics. |
|----------------------------------|
|                                | AS152s Baseline N = 75 | AS152s Week 24 N = 67 | Indiana on ART N = 46 | Indiana not on ART N = 39 |
| Age, years                      | 35 ± 8                | 35 ± 8                | 40 ± 8                | 38 ± 11               |
| Male sex, %                     | 92                    | 94                    | 63                    | 79                    |
| Race/Ethnicity %                |                       |                       |                       |                       |
| White, not Hispanic             | 55                    | 58                    | 63                    | 56                    |
| Black                            | 25                    | 25                    | 33                    | 41                    |
| White, Hispanic                  | 15                    | 12                    | 2                     | 0                     |
| Other                            | 5                     | 5                     | 2                     | 3                     |
| Time on ART                      | –                     | 24 weeks              | 40 months             | –                     |
| CD4, median (interquartile range)| 251 (129,369)         | 391 (272,560)         | 464 (362,761)         | 322 (216,432)         |
| Log$_{10}$ HIV RNA               | 4.9 ± 0.6             | 1.9 ± 0.6             | 2.9 ± 0.7             | 4.2 ± 1.1             |
| % HIV RNA <400 copies/mL         | 0                     | 92                    | 84                    | 11                    |
| sCD14, 10$^6$ pg/mL             | 2.14 ± 0.62           | 2.0 ± 0.64            | 1.72 ± 0.40           | 1.72 ± 0.47           |
| LPS, pg/mL                      | 32 ± 21               | 40 ± 32*              | 33 ± 24               | 26 ± 16               |
| % FMD, median (interquartile range)| 4.02 (1.98, 5.51) | 5.46 (3.35, 6.78) | 5.21 (2.25, 7.12) | 5.19 (2.50, 6.90) |

Values are means (± standard deviation) except where noted. ART – antiretroviral therapy. sCD14 – soluble CD14. LPS – lipopolysaccharide. FMD - Flow mediated dilation.

*Includes all subject data from baseline AS152s evaluations and all subjects in the Indiana cross-sectional study.

**Table 2. Pearson Correlation Coefficients of Markers of Microbial Translocation with Brachial Artery Flow-Mediated Dilation.**

|                                | All subjects* | AS152s Baseline | AS152s Week 24 | Indiana on ART | Indiana not on ART |
|--------------------------------|---------------|-----------------|----------------|----------------|--------------------|
| N                              | 160           | 75              | 67             | 46             | 39                 |
| sCD14                          | –0.15         | –0.05           | –0.09          | –0.04          | –0.23              |
| P                               | 0.07          | 0.07            | 0.5            | 0.9            | 0.2                |
| LPS                            | –0.06         | 0.07            | –0.2           | –0.33          | 0.16               |
| P                               | 0.45          | 0.5             | 0.2            | 0.02           | 0.3                |

*Includes all subject data from baseline AS152s evaluations and all subjects in the Indiana cross-sectional study.

ART – antiretroviral therapy. sCD14 – soluble CD14. LPS – lipopolysaccharide. Significant correlations are shown in bold.

doi:10.1371/journal.pone.0042624.t002

doi:10.1371/journal.pone.0042624.g001
LPS levels and FMD was not seen in those individuals not on ART or in those on short-term (24 weeks) ART. Soluble CD14 levels were not significantly correlated with FMD in any analyses. However, LPS is directly involved in the causal pathway of endothelial dysfunction [15,16] and thus may be a superior marker for this effect than a marker of monocyte activation such as CD14 which does not directly activate endothelial cells. We speculate that the effect of LPS on endothelial function was seen only among those on longer term ART because it may require a longer duration of ART for the effects of persistent microbial translocation to be detected without the influence of other HIV-related disease complications and their associated inflammation. Further studies will need to be completed in order to make any definitive conclusions. LPS levels did not decrease and unexpectedly increased after 24 weeks of ART in the ACTG subjects, which may be an insufficient duration of treatment to detect reduced microbial translocation as was reported by Brenchley [14] who studied subjects after 48 weeks of ART.

Most [20,21,22,23], but not all [24,25], studies have shown that microbial translocation is greater with more advanced HIV infection. Chronic, low-level increases in circulating LPS represent a major pro-inflammatory mediator of atherosclerosis [26]. Increased levels of circulating LPS were a major risk factor for carotid atherosclerosis and have been associated with a variety of chronic bacterial infections in the general population [27]. Chronic infections conferred increased risk of atherosclerosis development even in low-risk subjects free of conventional cardiovascular disease risk factors [27]. Our results suggest that microbial translocation likely contributes to the increased cardiovascular disease risk in chronic treated HIV infection.

Limitations of this study include the relatively small number of subjects in the various subgroups, including those on prolonged ART. The cross-sectional nature of the Indiana study precludes observation of changes over time. The short duration of ART in the ACTG 5152s subjects may have prevented detection of a relationship between FMD and microbial translocation that may have occurred with a longer duration of treatment. Finally, differences in FMD may not necessarily translate into lesser long-term cardiovascular disease risk.

We conclude that in HIV-infected individuals on prolonged ART, greater degrees of microbial translocation, as reflected by higher circulating LPS levels, are associated with worse endothelial function. Because persistent microbial translocation may contribute to the increased cardiovascular disease risk observed in individuals on long-term ART, measures to reduce microbial translocation in HIV-infected patients may be warranted as an intervention to reduce chronic disease risk.

Acknowledgments

The authors gratefully acknowledge the contributions of the subjects and members of ACTG 3142 and 5152s protocol teams as well as the staff of the Indiana University General Clinical Research Center, and to Kathy L. Clayton and Gina-Bob Dubé for managing the references. Results were presented in part at the 12th International Workshop on Adverse Drug Reactions and Co-morbidities in HIV, London, UK, November 2010.

Author Contributions

Conceived and designed the experiments: EB MD JS SG. Analyzed the data: CS. Contributed reagents/materials/analysis tools: GA AR. Wrote the paper: EB MD.

References

1. Triant VA, Lee H, Hadigan G, Grinspoon S (2007) Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. Journal of Clinical Endocrinology & Metabolism 92: 2506–2512.
2. Anderson TJ (2007) Prognostic significance of brachial flow-mediated vasodilation. Circulation 115: 2373–2375.
3. Kinlay S, Ganz P (1997) Role of endothelial dysfunction in coronary artery disease and implications for therapy. Am J Cardiol 80: 111–16.
4. Stein JH, Klein MA, Belliveau JL, McBride PE, Wiebe DA, et al. (2001) Use of human immunodeficiency virus type 1 protease inhibitors is associated with atherogenic lipoprotein and endothelial dysfunction. Circulation 104: 257–262.
5. Torriani FJ, Komarow L, Parker RA, Cotter BR, Carney JS, et al. (2000) Endothelial function in human immunodeficiency virus-infected antiretroviral naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. Journal of the American College of Cardiology 32: 569–576.
6. Solages A, Vida JA, Thornton DJ, Murray J, Heeren T, et al. (2006) Endothelial function in HIV-infected persons. Clinical Infectious Diseases 43: 1295–1392.
7. Grinspoon S, Carr A (2005) Cardiovascular risk and body-fat abnormalities in HIV-infected adults. New England Journal of Medicine 352: 48–62.
8. Dubé MP, Shen G, Greenwald M, Mather KJ, Gupta SK (2010) Relationship of body composition, metabolic status, antiretroviral use, and HIV disease factors to endothelial dysfunction in HIV-infected subjects. AIDS Res Hum Retrorm 26: 847–854.
9. Murphy RI, Berenzo B, Zala C, Fichtenbaum C, Dubé MP, et al. (2010) Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy. AIDS 24: 885–890.
10. Hsue PY, Hunt PW, Wu Y, Schnell A, Ho JE, et al. (2005) Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients. AIDS 23: 2021–2027.
11. Nolan D, Watts GF, Herrmann SE, French MA, John M, et al. (2003) Endothelial function in HIV-infected patients receiving protease inhibitor therapy does improve immune competence affect cardiovascular risk? QJM 96: 825–832.
12. Fries-Moller N, Sabin CA, Weber R, d’Arminio Monfosi A, El-Sadr WM, et al. (2003) Combination antiretroviral therapy and the risk of myocardial infarction. New England Journal of Medicine 349: 1993–2003.
13. Sandgren T, Clay SH, Raby E, Guzic A, Flahm J, et al. (2008) Rapid onset of intestinal epithelial barrier dysfunction in primary human immunodefiency virus infection is driven by an imbalance between immune response and mucosal repair and regeneration. Journal of Virology 82: 538–545.
14. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, et al. (2006) Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nature Medicine 12: 1365–1371.
15. Brenchley JM, Price DA, Douek DC (2006) HIV disease: fallout from a mucosal catastrophe? Nature Immunology 7: 235–239.
16. Dauphinee SM, Karsan A (2006) Lipopolysaccharide signaling in endothelial cells. Laboratory Investigation 86: 9–22.
17. Lepper PM, Kleber ME, Grammer TB, Hoffmann K, Dietz S, et al. (2011) Lipopolysaccharide-binding protein (LBP) is associated with total and cardiovascular mortality in individuals with or without stable coronary artery disease–results from the Ludwigshafen Risk and Cardiovascular Health Study (LURIC). Atherosclerosis 219: 291–297.
18. Yehoah J, Crouse JR, Hsu FC, Burke GL, Herrington DM (2007) Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: The Cardiovascular Health Study. Circulation 115: 2390–2397.
19. Riddler SA, Li X, Ottes J, Post W, Pallela F, et al. (2008) Antiretroviral therapy is associated with an atherogenic lipoprotein phenotype among HIV-1-infected men in the Multicenter AIDS Cohort Study. Journal of Acquired Immune Deficiency Syndromes: JAIDS 49: 281–289.
20. Cassol E, Rossouw T, Sebregts G, Cassol S (2011) Microbial translocation: a marker of advanced HIV-1 infection and a predictor of treatment failure? Journal of Infectious Diseases 203: 747–748.
21. Cassol E, Malfield S, Makaha P, van der Merwe S, Cassol S, et al. (2010) Persistent microbial translocation and immune activation in HIV-1-infected South Africans receiving combination antiretroviral therapy. Journal of Infectious Diseases 202: 723–733.
22. Ancuta P, Kamat A, Kunstman KJ, Kim E-Y, Autissier P, et al. (2008) Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS ONE [Electronic Resource] 3: e2516.
23. Nowrouzzadeh S, Mannon F, da Silva Z, Repits J, Dabo B, et al. (2010) Microbial translocation correlates with the severity of both HIV-1 and HIV-2 infections. Journal of Infectious Diseases 201: 1150–1154.
24. Redd AD, Gray RH, Quinn TC (2011) Is microbial translocation a cause or consequence of HIV disease progression? Journal of Infectious Diseases 203: 744–745; author reply 746.
25. Redd AD, Dubois D, Bream JH, Charvat B, Laszendecker O, et al. (2009) Microbial translocation, the innate cytokine response, and HIV-1 disease progression in Africa. Proceedings of the National Academy of Sciences of the United States of America 106: 6718–6723.
26. Stoll LL, Denning GM, Weintraub NL (2004) Potential role of endotoxin as a proinflammatory mediator of atherosclerosis. Arteriosclerosis, Thrombosis & Vascular Biology 24: 2227–2236.

27. Wiedermann CJ, Kiechl S, Dunzendorfer S, Schratzberger P, Egger G, et al. (1999) Association of endotoxemia with carotid atherosclerosis and cardiovascular disease: prospective results from the Bruneck Study. Journal of the American College of Cardiology 34: 1973–1981.